


ABSTRACT OF THE DISCLOSURE

The present invention provides compounds and pharmaceutical formulations useful as progesterone receptor agonists and antagonists and having the general formula:



5

wherein:

A is O, S, or NR⁴;

B is a bond or CR⁵R⁶;

R⁴, R⁵, and R⁶ are H, C₁ to C₆ alkyl, C₂ to C₆ alkenyl, C₂ to C₆ alkynyl, C₃ to

10 C₈ cycloalkyl, C₃ to C₈ cycloalkyl, aryl, or heterocyclic ring, or R⁴ and R⁵ form a 5 to 7 membered ring; R¹ is H, OH, NH₂, C₁ to C₆ alkyl, C₃ to C₆ alkenyl, alkynyl, or COR⁷;

R² is H, halogen, CN, NO₂, C₁ to C₆ alkyl, C₁ to C₆ alkoxy, or C₁ to C₆ aminoalkyl; R³ is a substituted benzene ring or heterocyclic ring; Q is O, S, NR⁸, or CR⁹R¹⁰; or a pharmaceutically acceptable salt thereof. The invention also includes methods of

15 contraception and methods of treating or preventing maladies associated with the progesterone receptor.

10074763.021202